Indications for CRIXIVAN:
Take with water on an empty stomach or with a light meal. 800mg every 8 hours. Concomitant rifabutin: 1g indinavir every 8 hours and reduce rifabutin dose by ½. Hepatic insufficiency, or concomitant ketoconazole, itraconazole or delavirdine: 600mg indinavir every 8 hours.
Not established. 3–18yrs: doses of 500mg/m2 every 8 hours have been used; see full labeling.
Concomitant alfuzosin, amiodarone, cisapride, lovastatin, simvastatin, oral midazolam, triazolam, alprazolam, lurasidone, pimozide, ergots, sildenafil (as Revatio; for PAH treatment).
Maintain adequate hydration. Discontinue or suspend therapy during acute nephro- or urolithiasis. Risk of acute hemolytic anemia; discontinue if occurs. Hepatic impairment. Monitor for hyperglycemia. Diabetes. Hemophilia (monitor for spontaneous bleeding). Asymptomatic severe leukocyturia: monitor urinalyses. Children (increased risk of nephro- or urolithiasis). Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.
HIV-1 protease inhibitor.
See Contraindications. Rifampin, St. John's wort, atazanavir, salmeterol, fluticasone (w. concomitant potent CYP3A4 inhibitor): not recommended. Caution with atorvastatin and rosuvastatin; titrate, use lowest necessary dose and monitor. Potentiates PDE5 inhibitors, IV midazolam, trazodone, bosentan (reduce doses; see full labeling); antiarrhythmics, rifabutin, calcium channel blockers, clarithromycin, immunosuppressants, others metabolized by CYP3A4. Plasma levels increased by itraconazole, ketoconazole, delavirdine, CYP3A4 inhibitors. Plasma levels reduced by efavirenz, rifabutin, venlafaxine, phenobarbital, phenytoin, carbamazepine, other CYP3A4 inducers. Avoid concomitant colchicine in renal or hepatic impairment; otherwise: reduce dose: see full labeling. Separate dosing of indinavir and didanosine by at least 1 hour and give both on empty stomach.
Nephro- or urolithiasis, asymptomatic hyperbilirubinemia, tubulointerstitial nephritis, abdominal pain, nausea, vomiting, headache, back pain, pruritus, increased cholesterol, hepatitis, hyperglycemia, fat redistribution, renal failure, immune reconstitution syndrome.
Register pregnant patients exposed to indinavir by calling (800) 258-4263.